Top Markets
#1 Siren Siren +39.86%
#2 RedStone RedStone +23.17%
#3 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +22.68%
#4 Perle Perle +15.69%
#5 Ocean Protocol Ocean Protocol +15.26%
#6 KUB Coin KUB Coin +14.31%
#7 Verus Coin Verus Coin +13.51%
#8 Cysic Cysic +10.93%
#9 Nosana Nosana +10.32%
#10 Quack AI Quack AI +10.31%
Coin of the day
Siren Siren
설정
언어
한국어
통화
USD
테마
VistaGen Therapeutics, Inc. VistaGen Therapeutics, Inc.

VistaGen Therapeutics, Inc.

VTGN
주식 순위 #31938
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical entity... VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical entity dedicated to advancing and commercializing innovative medications for anxiety, depression, and various other disorders impacting the central nervous system (CNS). A key component of its CNS pipeline is PH94B, a fast-acting neuroactive nasal spray currently in Phase III trials for the rapid treatment of anxiety in adults experiencing social anxiety disorder. PH94B also shows potential for addressing a broader spectrum of anxiety conditions, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder (PTSD), pre-procedural anxiety, and panic disorders. The company's CNS development initiatives further encompass PH10, another quick-acting neuroactive nasal spray, which is in preparation for Phase 2B clinical assessment as a standalone therapy for major depressive disorder (MDD). Additionally, VistaGen is developing AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is being investigated in conjunction with oral probenecid for its potential application in treating levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. VistaGen has established various collaborations, including a contract research and development agreement with Cato Research Ltd., a licensing agreement with Pherin Pharmaceuticals, Inc., and a license and collaboration agreement with EverInsight Therapeutics Inc. Founded in 1998, VistaGen Therapeutics, Inc. is headquartered in South San Francisco, California.
주가
$0.2619
마지막 동기화: 2026-08-17
시가총액
$11.62M
변동 (1일)
-2.13%
변동 (1년)
-92.30%
국가
US
거래 VistaGen Therapeutics, Inc. (VTGN)

카테고리

Healthcare
VistaGen Therapeutics, Inc. (VTGN)의 주가 이력
최고 종가: $0.27 (2026-08-01 기준)

최저 종가: $1.53K (2011-06-01 기준)
VistaGen Therapeutics, Inc.의 주가 이력 (2011 ~ 2026)
연간 주가 성과
연도 성과
2026 (TTM) -36.45%
2025 2.70%
2024 -46.68%
2023 39.81%
2022 -93.85%
2021 73.02%
2020 65.87%
2019 -58.43%
2018 30.09%
2017 -67.26%
2016 -39.96%
2015 -31.19%
2014 31.23%
2013 -53.04%
2012 -75.74%
2011 0.00%
유사 기업 또는 경쟁사의 주가
회사 주가 변동률 1년% 국가
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $515.58 32.24%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $992.01 50.00%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $111.75 -36.57%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $736.64 6.99%
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 $1.06K -7.22%
KR